Other Events ·
Ligand stockholders approve amended 2002 Stock Incentive Plan, elect eight directors
LGNDLigand Pharmaceuticals Inc
At its 2026 Annual Meeting on June 5, 2026, Ligand Pharmaceuticals stockholders approved an amendment and restatement of the Company's 2002 Stock Incentive Plan. Stockholders also elected eight members to the Board of Directors, ratified Ernst & Young LLP as the independent auditor, and approved a non-binding advisory resolution on executive compensation. Ligand Pharmaceuticals is a biopharmaceutical company that develops and licenses therapeutic proteins and other drug candidates.